13D Filings
Neuphoria Therapeutics Inc.
NEUP
Amendment
Ownership

16.30%

Total Shares

875,328

Issuer CIK

1191070

CUSIP

64136E102

Event Date

Dec 1, 2025

Accepted

Dec 2, 2025, 08:20 AM

Reporting Persons (2)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Lynx1 Capital Management LP
Partnership
16.30%875,3280875,328
Weston Nichols
Individual
16.30%875,3280875,328
Disclosure Items (4)

Security Title

Common Stock, par value $0.00001 per share

Issuer Name

Neuphoria Therapeutics Inc.

Issuer Address

100 SUMMIT DR, BURLINGTON, MA, 01803

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On December 2, 2025, the Reporting Persons delivered a letter to the Board which contained a new non-binding proposal (the "Recalculated Initial Offer") to acquire, through one or more managed investment funds and vehicles affiliated with the Investment Manager, all of the outstanding shares of capital stock of the Company for a price of $4.75 per share in cash. The foregoing description of the Recalculated Initial Offer does not purport to be complete and is qualified in its entirety by reference to the Recalculated Initial Offer, a copy of which is filed as an exhibit hereto and is incorporated herein by reference.

Item 6 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 4 of this Amendment No. 4 is incorporated herein by reference.

Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 99.4 Recalculated Initial Offer, dated December 2, 2025

Neuphoria Therapeutics Inc. — Schedule 13D | 13D Filings